急性心肌梗死期心血管并发症高危患者应用Inclusiran的体会

IF 0.5 4区医学 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS

Kardiologiya Pub Date : 2025-06-02 DOI:10.18087/cardio.2025.5.n2893

A V Khripun, E S Godunko, Yu Yu Gridneva, D O Rozhkov, A A Terentyev

{"title":"急性心肌梗死期心血管并发症高危患者应用Inclusiran的体会","authors":"A V Khripun, E S Godunko, Yu Yu Gridneva, D O Rozhkov, A A Terentyev","doi":"10.18087/cardio.2025.5.n2893","DOIUrl":null,"url":null,"abstract":"Aim To evaluate the effect of intensive lipid-lowering therapy (LLT), including inclisiran prescribed in the acute phase of ST-segment elevation myocardial infarction (STEMI), on lipid profile in patients with extremely high risk (EHR) of cardiovascular complications (CVC).Material and methods This prospective single-center clinical study included 20 patients (mean age 58.45±2.43 years, 75% men) with EHR of CVC and STEMI. All patients were prescribed combination LLT, including inclisiran. Lipid profile parameters were assessed 8±1 days after the initiation of therapy. Statistical analysis was performed with a STATISTICA 13.3 software.Results Analysis of the lipid-lowering effect of inclisiran showed a significant decrease in total cholesterol from 5.13±0.29 to 2.81±0.26 mmol/l (45.2%; p<0.001) and low-density lipoprotein cholesterol (LDL-C) from 3.59±0.23 to 1.60±0.23 mmol/l (55.4%; p<0.001).Conclusion The study showed a possibility of achieving statistically and clinically significant reduction in LDL-C in patients with EHR of CVC in the acute period of STEMI with the combination therapy including inclisiran during the inpatient treatment.","PeriodicalId":54750,"journal":{"name":"Kardiologiya","volume":"65 5","pages":"9-15"},"PeriodicalIF":0.5000,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Experience of Using the Drug Inclusiran in Patients With an Extremely High Risk Of Developing Cardiovascular Complications in The Acute Period of Myocardial Infarction.\",\"authors\":\"A V Khripun, E S Godunko, Yu Yu Gridneva, D O Rozhkov, A A Terentyev\",\"doi\":\"10.18087/cardio.2025.5.n2893\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Aim To evaluate the effect of intensive lipid-lowering therapy (LLT), including inclisiran prescribed in the acute phase of ST-segment elevation myocardial infarction (STEMI), on lipid profile in patients with extremely high risk (EHR) of cardiovascular complications (CVC).Material and methods This prospective single-center clinical study included 20 patients (mean age 58.45±2.43 years, 75% men) with EHR of CVC and STEMI. All patients were prescribed combination LLT, including inclisiran. Lipid profile parameters were assessed 8±1 days after the initiation of therapy. Statistical analysis was performed with a STATISTICA 13.3 software.Results Analysis of the lipid-lowering effect of inclisiran showed a significant decrease in total cholesterol from 5.13±0.29 to 2.81±0.26 mmol/l (45.2%; p<0.001) and low-density lipoprotein cholesterol (LDL-C) from 3.59±0.23 to 1.60±0.23 mmol/l (55.4%; p<0.001).Conclusion The study showed a possibility of achieving statistically and clinically significant reduction in LDL-C in patients with EHR of CVC in the acute period of STEMI with the combination therapy including inclisiran during the inpatient treatment.\",\"PeriodicalId\":54750,\"journal\":{\"name\":\"Kardiologiya\",\"volume\":\"65 5\",\"pages\":\"9-15\"},\"PeriodicalIF\":0.5000,\"publicationDate\":\"2025-06-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Kardiologiya\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.18087/cardio.2025.5.n2893\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Kardiologiya","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.18087/cardio.2025.5.n2893","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

摘要

目的评价st段抬高型心肌梗死（STEMI）急性期强化降脂治疗（LLT）（包括inclisiran）对心血管并发症（CVC）极高危（EHR）患者血脂的影响。材料与方法本前瞻性单中心临床研究纳入20例CVC和STEMI EHR患者（平均年龄58.45±2.43岁，男性75%）。所有患者均给予联合LLT治疗，包括昔兰。在治疗开始后8±1天评估血脂参数。统计学分析采用STATISTICA 13.3软件。结果降脂效果分析显示，总胆固醇由5.13±0.29降至2.81±0.26 mmol/l (45.2%；p<0.001)，低密度脂蛋白胆固醇（LDL-C）从3.59±0.23 mmol/l降至1.60±0.23 mmol/l (55.4%；术中,0.001)。结论本研究显示，在STEMI急性期CVC EHR患者在住院期间联合应用包括inclisiran在内的治疗，有可能实现具有统计学意义和临床意义的LDL-C降低。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

The Experience of Using the Drug Inclusiran in Patients With an Extremely High Risk Of Developing Cardiovascular Complications in The Acute Period of Myocardial Infarction.

Aim To evaluate the effect of intensive lipid-lowering therapy (LLT), including inclisiran prescribed in the acute phase of ST-segment elevation myocardial infarction (STEMI), on lipid profile in patients with extremely high risk (EHR) of cardiovascular complications (CVC).Material and methods This prospective single-center clinical study included 20 patients (mean age 58.45±2.43 years, 75% men) with EHR of CVC and STEMI. All patients were prescribed combination LLT, including inclisiran. Lipid profile parameters were assessed 8±1 days after the initiation of therapy. Statistical analysis was performed with a STATISTICA 13.3 software.Results Analysis of the lipid-lowering effect of inclisiran showed a significant decrease in total cholesterol from 5.13±0.29 to 2.81±0.26 mmol/l (45.2%; p<0.001) and low-density lipoprotein cholesterol (LDL-C) from 3.59±0.23 to 1.60±0.23 mmol/l (55.4%; p<0.001).Conclusion The study showed a possibility of achieving statistically and clinically significant reduction in LDL-C in patients with EHR of CVC in the acute period of STEMI with the combination therapy including inclisiran during the inpatient treatment.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Kardiologiya 医学-心血管系统

CiteScore

1.70

自引率

20.00%

发文量

审稿时长

3-8 weeks

期刊介绍： “Kardiologiya” (Cardiology) is a monthly scientific, peer-reviewed journal committed to both basic cardiovascular medicine and practical aspects of cardiology. As the leader in its field, “Kardiologiya” provides original coverage of recent progress in cardiovascular medicine. We publish state-of-the-art articles integrating clinical and research activities in the fields of basic cardiovascular science and clinical cardiology, with a focus on emerging issues in cardiovascular disease. Our target audience spans a diversity of health care professionals and medical researchers working in cardiovascular medicine and related fields. The principal language of the Journal is Russian, an additional language – English (title, authors’ information, abstract, keywords). “Kardiologiya” is a peer-reviewed scientific journal. All articles are reviewed by scientists, who gained high international prestige in cardiovascular science and clinical cardiology. The Journal is currently cited and indexed in major Abstracting & Indexing databases: Web of Science, Medline and Scopus. The Journal''s primary objectives Contribute to raising the professional level of medical researchers, physicians and academic teachers. Present the results of current research and clinical observations, explore the effectiveness of drug and non-drug treatments of heart disease, inform about new diagnostic techniques; discuss current trends and new advancements in clinical cardiology, contribute to continuing medical education, inform readers about results of Russian and international scientific forums; Further improve the general quality of reviewing and editing of manuscripts submitted for publication; Provide the widest possible dissemination of the published articles, among the global scientific community; Extend distribution and indexing of scientific publications in major Abstracting & Indexing databases.